Subscribe to magazine
Subscribe to newsletters
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Radiation Dose management
Intravascular imaging systems
Peripheral Artery Disease
Leads, implantable devices
Implantable cardioverter defibrillators (ICD)
Cardiac resynchronization therapy devices (CRT)
Heart Valve Technology
Left atrial appendage (LAA) occluders
Structural heart occluders/closure devices
Clinical decision support
Regado Biosciences Inc.
120 Mountain View Boulevard
Basking Ridge, NJ 07920
March 25, 2015
Novel Anti-Clotting Therapy in Halted Trial No Better Than Existing Agents
A novel therapy that would allow doctors to turn the body’s blood clotting ability off and on in a more controlled way...
July 30, 2014
REGULATE-PCI Trial Testing Anticoagulant Pegnivacogin Anticoagulant Halted
July 30, 2014 — Regado Biosciences announced earlier this month it has voluntarily paused enrollment in its REGULATE-...
April 07, 2011
New Anticoagulation Agent Shows Positive Results in Clinical Trial
April 7, 2011 – Primary results from the RADAR Phase 2b clinical trial were announced at the American College of...
April 01, 2011
Clinical Trial Results for Anticoagulation System to be Presented at ACC
April 1, 2011 –Results from the RADAR Phase 2b clinical trial will be announced at the i2 Summit during the American...
September 10, 2009
RADAR Phase 2b Study Examines REG1 Anticoagulant in ACS Patients
September 10, 2009 – Regado Biosciences said this week it enrolled the first patient in a phase 2b, randomized,...
Scranton Gillette Communications
. All Rights Reserved.
Terms and Conditions